IPSC
Century Therapeutics Inc

518
Loading...
Loading...
News
all
press releases
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Century Therapeutics (IPSC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·2mo ago
News Placeholder
More News
News Placeholder
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
Century Therapeutics (IPSC) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Zacks·2mo ago
News Placeholder
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Century Therapeutics (IPSC) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Zacks·3mo ago
News Placeholder
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Zacks·3mo ago
News Placeholder
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Zacks·4mo ago
News Placeholder
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Zacks·4mo ago
News Placeholder
Buy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of Competitors
In a report released yesterday, Charlie CY Yang from Bank of America Securities maintained a Buy rating on Century Therapeutics (IPSC Research Re...
TipRanks Financial Blog·1y ago
News Placeholder
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D...
Benzinga·1y ago
News Placeholder
Head-To-Head Review: Century Therapeutics (NASDAQ:IPSC) and Medivir AB (publ) (OTCMKTS:MVRBF)
Medivir AB (publ) (OTCMKTS:MVRBF - Get Free Report) and Century Therapeutics (NASDAQ:IPSC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two...
Zolmax·1y ago

Latest IPSC News

View

Advertisement. Remove ads.

Advertisement. Remove ads.